In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months
about
Modeling the within-host dynamics of HIV infectionTargeting the Brain Reservoirs: Toward an HIV CureDepletion of latent HIV-1 infection in vivo: a proof-of-concept studyViral and latent reservoir persistence in HIV-1-infected patients on therapyART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremiaA stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patientsModeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineageShort-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapyExpression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma.Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.Pharmaceutical approaches to eradication of persistent HIV infection.Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levelsTheoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infectionLow-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.Cell-associated HIV RNA: a dynamic biomarker of viral persistence.Regulation of HIV-1 latency by T-cell activation.Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy.Contribution of follicular dendritic cells to persistent HIV viremia.Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography.Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection.Improving combination antiretroviral therapy by targeting HIV-1 gene transcription.Latently infected cell activation: a way to reduce the size of the HIV reservoir?Mathematical modeling of within-host Zika virus dynamicsCD8+ lymphocyte control of SIV infection during antiretroviral therapy
P2860
Q21245370-FD50A0CA-AB09-4C62-8E9B-1BC5F5739C7FQ28075694-F593B017-5845-4F92-95E4-B931BEF1B289Q28111910-3ED7A85E-4305-4ED7-A654-A5A2A84D3F48Q28469057-1EEB2E99-E709-4E19-9821-B3AC9940E414Q28469175-9C60B414-0876-4AAA-BDD7-76C34DC3231DQ28477926-B485CBB3-4B12-4AD9-88DE-01C0EBCBC635Q33510903-E7642A03-ED4C-445E-89A9-C453DCCBF06BQ33864438-26AA9DDE-583D-4BDC-8AFD-214F9A125BFBQ33962223-28D414D0-3C5C-48AE-9B23-BFFA16318F56Q34730335-EDD9FBCD-17A6-4FE3-9541-AEFEB84D7D44Q34869426-6C7AC667-EFA7-42BA-8E60-6EA28149827AQ34941973-A5B7488B-4727-450D-BD67-9D5F65CF7C3EQ36058328-A229A959-E3C0-44DB-BC58-9E4CB350DE22Q36464609-9E5053F6-982B-46F4-8200-83E098B4E746Q36499290-9D15F990-EC58-4694-A6C5-45AB51D633CEQ36798408-33567DD6-7A5F-4B3F-A7BB-A4DB6068BDFAQ36887625-7BE87730-C961-4D32-B090-B798A3DD01BDQ36977630-76387897-B236-4E28-AB58-3DA247B24C67Q36978662-4206224A-1D52-49A9-8854-BF6D6A3B816EQ37392720-4C3C0CC4-4E36-4D98-B594-2F0FF58FA22CQ37393518-37914A8A-5F4F-4317-8E0B-DBA392709178Q37511462-6DC78059-A368-4ACF-AD1A-65A49175FD6EQ38856263-5F073390-B937-4CBA-98FF-70B438D04AB4Q47311740-4E093E09-D3B9-4BC6-95B5-529693FD8D9EQ56336242-93A576D1-045D-4B9A-9E32-86B2D5B57C44Q57281967-3B494896-C674-464A-9998-A8CC9FFDF530
P2860
In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
In a subset of subjects on hig ...... , with a half-life of 6 months
@ast
In a subset of subjects on hig ...... , with a half-life of 6 months
@en
In a subset of subjects on hig ...... , with a half-life of 6 months
@nl
type
label
In a subset of subjects on hig ...... , with a half-life of 6 months
@ast
In a subset of subjects on hig ...... , with a half-life of 6 months
@en
In a subset of subjects on hig ...... , with a half-life of 6 months
@nl
prefLabel
In a subset of subjects on hig ...... , with a half-life of 6 months
@ast
In a subset of subjects on hig ...... , with a half-life of 6 months
@en
In a subset of subjects on hig ...... , with a half-life of 6 months
@nl
P2093
P2860
P1433
P1476
In a subset of subjects on hig ...... , with a half-life of 6 months
@en
P2093
Geethanjali Dornadula
Joseph Kulkosky
Julie Sullivan
Michele Di Mascio
Roger J Pomerantz
P2860
P304
P356
10.1128/JVI.77.3.2271-2275.2003
P407
P577
2003-02-01T00:00:00Z